Serum levels of advanced glycation end products are increased in patients with type 2 diabetes and coronary heart disease.

Kilhovd, B K; Berg, T J; Birkeland, K I; Thorsby, P; Hanssen, K F

Kilhovd, B K; Berg, T J; Birkeland, K I; Thorsby, P; Hanssen, K F.

Affiliation

Kilhovd BK; Aker Diabetes Research Centre, Department of Endocrinology, Aker University Hospital, Oslo, Norway. b.k.kilhovd@ioks.uio.no

Diabetes Care ; 22(9): 1543-8, 1999 Sep.

Article in En | MEDLINE | ID: mdl-10480523

Subject(s)

Coronary Disease/blood; Diabetes Mellitus, Type 2/blood; Diabetic Angiopathies/blood; Glycation End Products, Advanced/blood; Aged; Coronary Disease/etiology; Epitopes/blood; Female; Humans; Lysine/analogs & derivatives; Lysine/immunology; Male; Middle Aged; Multivariate Analysis; Risk Factors

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Glycation End Products, Advanced / Coronary Disease / Diabetes Mellitus, Type 2 / Diabetic Angiopathies Type of study: Clinical_trials / Etiology_studies / Risk_factors_studies Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: Diabetes Care Year: 1999 Type: Article Affiliation country: Norway

Search on Google

XML

PubMed Links